Radiologic Pathologic Correlation of Advanced MR Imaging to Guide the Biopsy of Cerebral Malignancies
This study is looking at whether a special type of MRI, called Advanced Magnetic Resonance Imaging (AMRI), can help doctors take more accurate biopsies of brain tumors. When you have a brain tumor, some parts can be more aggressive than others. Doctors want to biopsy the most aggressive part to get the best information. Researchers believe AMRI might help them find these aggressive areas better than standard methods. You would have an AMRI scan, which includes different types of imaging like perfusion scans (looking at blood vessels) and spectroscopy scans (looking at the tumor's chemistry), before your scheduled brain tumor removal surgery. The study will compare how well the AMRI-guided biopsies match the actual tumor grade compared to standard biopsies. This study is for adults aged 18 and older who have a suspected or confirmed brain tumor and are scheduled for surgery. The AMRI scan is not yet approved by the FDA and is only used for research.
- Study design
- This is an interventional study with an unclear phase, planning to enroll up to 62 participants. It is not specified if it is randomized or blinded.
- What's involved
- You will have an AMRI scan, which takes less than 1 hour, within two weeks before your standard brain tumor removal surgery. During surgery, up to 5 biopsies will be taken from different locations.
- Compensation
- There will be no cost to you for the advanced MRI, additional anesthesia, special pathology stains, and/or gene testing for this study.
- Follow-up
- The primary endpoints, which include comparing biopsy accuracy and target sample grading, are measured at 2 weeks after the biopsy.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Radiologic Pathologic Correlation of Advanced MR Imaging to Guide the Biopsy of Cerebral Malignancies
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Dawid Schellingerhout, MD · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Exclusion
What this trial measures
- Comparison of the Accuracy of the Pathological Grades of Tumor Observed at the Biopsy Locations Identified Using Conventional Versus Advanced Imaging2 weeks
Researchers wish to determine if the accuracy of the pathological grade observed at the biopsy sites identified by advanced imaging is higher than the grades observed at the biopsy sites identified by conventional imaging.
- Target Sample Grading2 weeks
The quantitative pathology markers compared between the conventional and advanced target specimens.